Instruction 1(b).

FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Check this box if no longer subject	STATEM
to Section 16. Form 4 or Form 5 obligations may continue. See	

## ENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Sinha Vikas  (Last) (First) (Middle)  C/O ALLOVIR, INC.					3. Da	Susuer Name and Ticker or Trading Symbol     Allovir, Inc. [ ALVR ]      Date of Earliest Transaction (Month/Day/Year)     07/28/2022								S. Relationship of Reporting Person(s) to Issuer (Check all applicable)     X Director X 10% Owner     X Officer (give title Other (specify below)      See Remarks						
1100 WINTER STREET  (Street)  WALTHAM MA 02451  (City) (State) (Zip)				4. If <i>i</i>	4. If Amendment, Date of Original Filed (Month/Day/Year)								Individual or Joint/Group Filing (Check Applicable Line)     X Form filed by One Reporting Person     Form filed by More than One Reporting Person							
Table I - Non-Derivat  1. Title of Security (Instr. 3)  2. Transaction Date (Month/Day/Ye					on Year)	2A. Deemed Execution Date,		te,	3. Transaction Code (Instr.		4. Securities Acquired (A) o Disposed Of (D) (Instr. 3, 4 a			5. Amount of		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership		
									Code	v	Amount	(A) or (D)	Price	Transact	ransaction(s) Instr. 3 and 4)				By	
Common Stock 07/28/202						22			<b>A</b> <sup>(1)</sup>		3,253,796	A	\$4.61	16,674,766		I		ElevateBio LLC <sup>(2)</sup>		
Common										938	,224		D							
		Tal	ole II								posed of, convertib				d					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Exec if any	Deemed cution Date, y y tth/Day/Year)	4. Transs Code 8)	<u> </u>	5. Nu of Deriv Secu Acqu (A) or Dispo of (D) (Instrand 5	rities iired r osed ) : 3, 4	Exp (Mo	iration nth/Day	(Year)	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)  Amount or Number of Title Shares		8. Price of Derivative Security (Instr. 5)			10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		11. Nature of Indirect Beneficial Ownership (Instr. 4)	

## **Explanation of Responses:**

- 1. On July 28, 2022, ElevateBio LLC ("ElevateBio") acquired 3,253,796 shares of the Issuer's Common Stock in a registered direct offering for a purchase price of \$4.61 per share.
- 2. Shares held by ElevateBio. The Reporting Person is a director and Chief Financial Officer of ElevateBio, and may be deemed to have shared voting and investment power of the shares held by ElevateBio. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

## Remarks:

Officer Title: President and Chief Financial Officer

/s/ Brett Hagen, as Attorney-

08/01/2022

in-Fact

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.